Nano-X Imaging Ltd.

Nano-X Imaging Ltd. announced its 2026 Annual General Meeting of Shareholders to be held on September 17, 2026. Key proposals include the re-election of two Class III directors and an amendment to increase the authorized share capital by NIS 500,000, adding 50 million ordinary shares. Shareholders will also vote on two equity grants for CEO Erez Meltzer and the re-appointment of Kesselman & Kesselman (PwC) as independent auditors for fiscal year 2026. The meeting will also review the company's consolidated financial statements for the year ended December 31, 2025.

Nanox AI Ltd., a subsidiary of Nano-X Imaging Ltd., announced the optimization of its medical imaging AI application framework for Intel Core Ultra processors using Intel’s OpenVINO toolkit. This collaboration enables on-premise edge inference within healthcare environments, allowing organizations to deploy CT imaging AI applications while maintaining data within their own infrastructure. The optimized framework aims to help healthcare organizations derive additional clinical value from existing scans and support preventive care management by identifying chronic conditions.

Nano-X Imaging Ltd. has completed its previously reported registered direct offering, raising approximately $8.0 million in gross proceeds. The company sold 8,000,000 ordinary shares (or pre-funded warrants) and 8,000,000 ordinary warrants to a single long-term institutional investor. The net proceeds from the offering are intended for working capital and general corporate purposes.

Nano-X Imaging Ltd. announced a registered direct offering to a single institutional investor, expecting to raise approximately $8 million in gross proceeds. The offering includes 8,000,000 ordinary shares and warrants to purchase an equal number of shares, with a combined purchase price of $1.00 per share and warrant. Separately, the company disclosed an ongoing comprehensive impairment assessment for its Q2 2026 financial statements, which could lead to material differences from preliminary estimates.

Nano-X Imaging Ltd. filed a Form 6-K to include a legal opinion from Meitar Law Offices. This opinion confirms the validity of the remaining $53.9 million of ordinary shares that can be issued and sold under the company's Controlled Equity OfferingSM Sales Agreement, dated June 7, 2024. This filing is a procedural step to enable future share issuance under the existing shelf registration statement and prospectus supplement.

Nanox Imaging Ltd. announced that data from studies featuring its Nanox.AI cardiac solution (HealthCCSng) will be presented at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT). New abstracts from Brigham and Women’s Hospital highlight the FDA-cleared solution's high agreement with expert assessment and its potential role in supporting guideline-directed preventive care. The AI INFORM trial also demonstrates how AI-detected coronary calcium can help clinicians identify opportunities for preventive lipid-lowering therapy. Nanox.AI is also sponsoring a scientific session at the event.

Nano-X Imaging Ltd. reported Q1 2026 revenue of $4.3 million, an increase from $2.8 million in Q1 2025, but its GAAP net loss widened to $14.3 million. The company withdrew its 2026 revenue target and will no longer provide annual guidance due to variability in deployment timelines and revenue recognition. Management raised substantial doubt about its ability to continue as a going concern, citing insufficient cash for operations beyond one year. Additionally, a class action lawsuit was filed on June 12, 2026, alleging federal securities law violations.

Nanox announced it will report its financial results for the first quarter ended March 31, 2026, before market open on Thursday, June 25, 2026. The company will host a conference call at 8:30 a.m. ET on the same day, featuring CEO Erez Meltzer and CFO Ran Daniel, to discuss these results and provide a business update. Interested parties can register for the call or access the live webcast through links provided in the announcement.

Nano-X Imaging Ltd. announced that its U.S. subsidiary, Nanox Impact Inc., has signed a distribution agreement with NuvioDx LLC. This partnership aims to support the deployment of Nanox.ARC multi-source digital tomosynthesis systems across clinical sites in various U.S. states. The agreement strengthens Nanox's commercialization strategy and expands its channel partner network, leveraging NuvioDx's experience in medical imaging technology adoption.

Nano-X Imaging Ltd.'s U.S. subsidiary, Nanox Impact Inc., has signed a distribution agreement with Radiology Oncology Systems. This partnership will facilitate the commercial rollout of Nanox's FDA-cleared Nanox.ARC systems across the U.S. The collaboration aims to broaden access to advanced 3D imaging solutions in various clinical settings, including oncology-adjacent care environments, leveraging the partner's established network.